Is it time for increased pap performance? Cervical cancer and pap testing in women with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 16, Issue 1, 2010, Pages 175-176

  Minor, Melissa A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; CORTICOSTEROID; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT;

CANCER RISK; CANCER SCREENING; CONDYLOMA ACUMINATUM; CROHN DISEASE; ENTERITIS; HEALTH MAINTENANCE ORGANIZATION; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NOTE; PAPANICOLAOU TEST; PRIORITY JOURNAL; RISK ASSESSMENT; UTERINE CERVIX CANCER; WART VIRUS;

EID: 74049137781     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20987     Document Type: Note

References (15)

1. Bernatsky S, Ramsey-Goldman R, Gordon C, et al. Factors associated with abnormal Pap results in systemic lupus erythematous. Rheumatology. 2004;43:1386-1389.
2. Tam LS, Chan AY, Chan PK, et al. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematous: association with human papillomavirus infection. Arthritis Rheum. 2004;50:3619-3625.
3. Dhar JD, Kmak D, Bhan R, et al. Abnormal cervicovaginal cytology in women with lupus: a retrospective cohort study. Gynecol Oncol. 2001;82:4-6.
4. Seshadri L, George SS, Vasudevan B, et al. Cervical intraepithelial neoplasia and human papilloma virus infections in renal transplant recipients. Indian J Cancer. 2004;38:92-95.
5. Ozsaran AA, Ates T, Dikmen Y, et al. Evaluation of the risk of cervical intraepithelial neoplasia and human papilloma virus infection in renal transplant patients receiving immunosuppressive therapy. Eur J Gynaecol Oncol. 1999;20:127-130.
6. Malouf MA, Hopkins PM, Singleton L, et al. Sexual health issues after lung transplantation: importance of cervical screening. J Heart Lung Transplant. 2004;23:894-897.
7. Bhatia J, Bratcher J, Korelitz B, et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol. 2006;12:6167-6171.
8. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2007;102:1-6.
9. Singh H, Demers AA, Nugent Z, et al. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based-nested case-control study. Gastroenterology. 2009;136:451-458.
10. Huftless S, Fireman B, Kane S, et al. Screening differences and risk of cervical cancer in inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28:598-605.
11. Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91:854-862.
12. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-527.
13. ACOG practice bulletin: clinical management guidelines for obstetrician-gynecologists-no. 44, July 2003. Obstet Gynecol. 2003;102:203-213.
14. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2008: a review of current American Cancer Society guidelines and cancer screening issues. CA Cancer J Clin. 2008;58:161-179.
15. Long MD, Porter CQ, Sandler RA, et al. Suboptimal rates of cervical testing among women with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2008 [Epub ahead of print].